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Angiogenesis is an essential step in the repair process
that occurs after injury. In this study, we investigated
whether the angiogenic thymic peptide thymosin b4
(Tb4) enhanced wound healing in a rat full thickness
wound model. Addition of Tb4 topically or intraperi-
toneally increased reepithelialization by 42% over
saline controls at 4 d and by as much as 61% at 7 d
post-wounding. Treated wounds also contracted at
least 11% more than controls by day 7. Increased
collagen deposition and angiogenesis were observed in
Injury initiates a complex series of events. An essential stepin wound repair is angiogenesis, the formation of new bloodvessels from existing blood vessels. New vessels are necessaryfor supplying nutrients and oxygen to the cells involved inthe repair process, for removing debris, and for granulation
tissue formation. These blood vessels are a transient response to
the injury. Many new blood vessels form early, approximately 2 d
after injury in normal wound healing, and then atrophy when
healing is complete. The factors involved in triggering formation
and regression of the vessels are not clear. Known angiogenic
factors such as vascular endothelial growth factor, basic fibroblast
growth factor, transforming growth factor α and β, and thymosin
β4 (Tβ4) (Arnold et al, 1987; Dvonch et al, 1992; Frohm et al,
1996) have been found in wound fluid, but their actions in the
angiogenic response are not well defined. There is some evidence
from recent studies with neutralizing antibodies that basic fibroblast
growth factor and vascular endothelial growth factor contribute to
an angiogenic response after injury (Broadley et al, 1989; Nissen
et al, 1998).
Here we studied the effect of Tβ4 on wound healing. Tβ4 is a
43 amino acid, 4.9 kDa ubiquitous polypeptide found at concentra-
tions of 1 3 10–5 to 5.6 3 10–1 M in a variety of tissues and cell
types and was originally isolated from bovine thymus (Weber et al,
1992; Pantaloni and Carlier, 1993; Mihelic and Voelter, 1994;
Oates and Goldstein, 1995). Tβ4 can interact with G-actin and is
a major actin sequestering protein in cells (Cassimeris et al, 1992;
Sanders et al, 1992; Yu et al, 1993, 1994; Safer and Nachmias,
1994; Sanger et al, 1995). Tβ4 influences T cell differentiation (Hu
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the treated wounds. We also found that Tb4 stimulated
keratinocyte migration in the Boyden chamber assay.
After 4–5 h, migration was stimulated 2–3-fold over
migration with medium alone when as little as 10 pg
of Tb4 was added to the assay. These results suggest
that Tb4 is a potent wound healing factor with multiple
activities that may be useful in the clinic. Key words:
angiogenesis/migrations/reepithelialization/thymic peptides.
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et al, 1981; Low et al, 1981; Low and Goldstein, 1982) and appears
to play a role in the differentiation of other cell types. Endothelial
cell differentiation, in part, appears to be regulated by Tβ4. Matrigel,
a basement membrane matrix, stimulates the expression of Tβ4
mRNA several fold in human umbilical vein endothelial cells
(Grant et al, 1995). Tβ4 also stimulates endothelial cell migration
in vitro and in vivo, acting as a potent chemoattractive factor (Malinda
et al, 1997). In addition, Tβ4 mRNA levels are elevated in areas
of active neuronal growth and differentiation and around blood
vessels (Carpinterio et al, 1995), and as granulocytes and other
hemopoetic cells mature (Gondo et al, 1987; Hall, 1991; Gomez-
Marquez et al, 1989). The ability of Tβ4 to influence the differenti-
ation and migration of endothelial cells and the differentiation of
other cell types suggests that Tβ4 may be a useful agent to treat
wounds. Furthermore, Tβ4 levels are highest in platelets (Weber
et al, 1992), which are the first cells to enter the wound.
Due to the potential effects angiogenic compounds may have
on stimulating wound healing, we have been studying the effects
of angiogenic thymic peptides on tissue repair. We investigated the
ability of Tβ4 to influence wound healing using full thickness
punch wounds in rat skin. Tβ4 stimulated wound healing when
applied either topically or injected intraperitoneally. Reepithelializ-
ation and wound contraction were enhanced in treated wounds as
early as 4 d post-wounding. Further analysis showed that capillary
ingrowth is increased in treated wounds as is collagen deposition/
accumulation. Boyden chamber assays in vitro showed that Tβ4
stimulates keratinocyte migration. We conclude that Tβ4 has potent
wound healing effects in addition to angiogenesis and may be
useful in the clinic to treat normal and chronic wounds.
MATERIALS AND METHODS
Cell culture Primary keratinocytes were prepared from either BALB/C
or CD-1 newborn mice as described previously (Dlugosz et al, 1995). Cells
were plated in calcium- and magnesium-free Eagle’s minimal essential
medium (EMEM) containing 8% fetal calf serum treated with 8% Chelex
(Bio-Rad Laboratories, Hercules, CA), 20 units penicillin-streptomycin
per ml, and the calcium concentration was adjusted to 0.25 mM. The
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Figure 1. Diagram of an 8 mm full thickness
cutaneous rat punch wound. The wound
penetrates the epidermis (E) and dermis (D) and is
in contact with the fat and muscle (F) layer. The
reepithelialization (gap) and contraction of dermis
(width) are measured to calculate wound closure.
following day, cultures were washed with calcium- and magnesium-free
phosphate-buffered saline, treated briefly with Trypsin (Life Technologies,
Gaithersburg, MD), washed in culture medium, and resuspended in EMEM
(Life Technologies, Gaithersburg, MD) containing 0.05 mM calcium (cells
and media gifts of Laura Hansen, NCI, NIH). Cells were used immediately
in migration assays.
In vivo wound assay Six full thickness 8 mm punch biopsy wounds
were made on the dorsal surface of each rat as previously described
(Bhartiya et al, 1992; Sidhu et al, 1996). Tβ4 (synthetic GMP material, gift
from Alpha 1 Biomedical, Bethesda, MD) was applied topically at the time
of wounding (5 µg in 50 µl) and again after 48 h to three of the wounds
on each rat. Controls for the topical treatment (the three remaining wounds
on each rat) received identical amounts of saline at the time of wounding
and at 48 h. Alternatively, three rats received intraperitoneal injections of
Tβ4 (60 µg in 300 µl) at the time of wounding and every other day
thereafter for 7 d. Controls for these animals received identical amounts
of saline intraperitoneally on the same injection schedule. At days 4 and 7
post-wounding, wound tissue was collected and fixed in 10% buffered
formalin (intraperitoneal, n 5 18 samples; topical, n 5 9 samples). The
samples were sectioned, and sections from the middle of the wound were
stained with hematoxylin and eosin and Masson’s Trichrome (American
Histolabs, Gaithersburg, MD). This experiment was performed twice using
three rats for each test condition.
Morphometric measurements Histologic sections were used to
measure the reepithelialization and the contraction of the wound using an
ocular micrometer. Epidermal migration was determined by measuring the
lengths of the tongues of epithelium migrating from either side of the
wound over the wound bed from the zone of proliferation at the margin
of the uninjured and wounded skin. Epidermal thickness was also measured
beginning at the junction of the uninjured and proliferating epidermis.
The thickness was measured vertically from the basement membrane to
the most superficial layer of the migrating epidermis at every 200 microns.
The mean epidermal thickness of each migrating tongue of epidermis was
then computed for each wound. Vessel counts were performed by first
identifying vascular spaces by their endothelial lining. All such vessels in
the wound bed were counted, including those at the junction of the dermis
and the subcutis, since angiogenesis into the wounds occurs to a great
extent from these vessels. The numbers were averaged into vessel counts
per 10 high powered fields (403).
Migration assay Keratinocyte migration assays were carried out in
Boyden chambers using 12 µm pore polyester membranes (Poretics,
Livermore, CA) coated with 0.1 mg per ml solution of collagen IV in
dH2O (Trevigen, Gaithersburg, MD). Filters were then dried for at least
1 h. Cells were harvested using Versene or Trypsin (Life Technologies,
Gaithersburg, MD) and resuspended in EMEM with 0.05 mM Ca21. The
bottom chamber was loaded with EMEM containing 0.01, 0.1, 10, 100,
and 1000 ng synthetic Tβ4 (gift from Alpha 1 Biomedical, Bethesda, MD)
per ml. Conditioned medium from primary dermal fibroblasts (gift from
Laura Hansen, NCI, NIH) and/or keratinocyte growth factor (gift of Don
Bottaro, NCI, NIH) was added to several wells as a positive control. Cells
were added to the upper chamber at a concentration of 50,000 cells per
well. Chambers were incubated at 35°C/7% CO2 for 4–5 h and the
filters were then fixed and stained using Diff-Quik (Baxter Healthcare
Corporation, McGraw Park, IL). The cells that migrated through the filter
were quantitated by counting the center of each well at 103 using an
Olympus CK2 microscope. Each condition was assayed in triplicate wells
and each experiment was repeated four times with different preparations
of cells.
Figure 2. Tb4 increased gap closure when applied topically or
injected intraperitoneally. (a) Topical treatment with 5 µg of Tβ4 in
50 µl saline on the day of wounding and at 48 h, resulted in a 18% (612%)
decrease in gap length as compared with the saline controls as early as 4 d
after wounding. This trend continued to termination at day 7 (*p ø 0.04,
Student’s t-test). Measurements are expressed as the mean % decrease 6
SEM: day 4, n 5 8; day 7, control, n 5 7; treated, n 5 5. (b) Intraperitoneal
injection of Tβ4 (60 µg in 300 µl) on the day of wounding and subsequently
every other day also resulted in a 42% (69%) decrease in gap size relative
to saline-treated controls. This decrease was observed on the fourth day
post-wounding and continued through day 7 (**p ø 0.0007, Student’s
t-test). Measurements are expressed as the mean % decrease 6 SEM: day
4, control, n 5 16; treated, n 5 18; day 7, control, n 5 14; treated, n 5 16.
RESULTS
Reepithelialization and contraction of treated wounds The
effect of Tβ4 on wound healing was studied in a full thickness
cutaneous rat wound model. Figure 1 shows a diagram of the
wound site that extends from the epidermis to the fat/muscle
layer. This model allowed measurement of two parameters: the
reepithelialization (gap) and the contraction (width) of the wound.
Wounds treated topically with Tβ4 (5 µg per 50 µl) showed a 18%
(612%) decrease in gap as compared with saline-treated control
wounds as early as 4 d after injury (Fig 2a, n 5 8 evaluable
wounds). This increase in reepithelialization was also observed in
wounds treated for 7 d and the rate of gap closure was slightly
accelerated over that observed at day 4. A 62% (621%) decrease
in gap size was observed in the Tβ4-treated wounds (p ø 0.04).
Quantitation of epidermal migration showed a statistically significant
1.5-fold increase in migration of epidermal tongues over the wound
bed after topical treatment (Table 1). Intraperitoneal injection of
Tβ4 (60 µg per 300 µl) also resulted in enhanced wound healing.
Statistically significant differences were observed between the
control injections (saline, n 5 16 evaluable) and the Tβ4 injections
(n 5 18) (Fig 2b). There was a 42% (69%) decrease in gap size
at day 4 with Tβ4 treatment (p ø 0.0007). At day 7, a 61%
(611%) decrease in gap size was observed as compared with the
control (n 5 16 evaluable wounds Tβ4; 14 controls) (p ø 0.0002).
Quantitation of epidermal migration in intraperitoneally treated
wounds showed a statistically significant increase in migration of
epidermal tongues as compared with controls (Table 1). There
was no apparent difference in the thickness of the migrating
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epidermis between either of the Tβ4 treatments and the control
(Table 1). Histologic sections of the wounds clearly show increased
reepithelialization in the treated wounds as compared with controls
in 7 d wounds (Fig 3b and c vs a).
Contraction (width) of the wounds was also evaluated in both
topically and intraperitoneally treated wounds. After 4 d of Tβ4
treatment, wounds showed a 15% (67%) decrease in width as
compared with controls (Fig 4a, n 5 8 evaluable wounds) and
after 7 d a 24% (68%) decrease was observed (n 5 5 Tβ4; seven
controls). Intraperitoneal injections of Tβ4 resulted in an 18%
(64%) decrease in wound width as compared with controls on
day 4 and an 11% (64%) decrease on day 7 (Fig 4b). These data
demonstrate that Tβ4, when given either topically or systemically,
increases wound reepithelialization and contraction. Both topical
and systemic treatments appear to be equally effective. Lower doses
of Tβ4 were tested, including 2.5 µg and 0.5 µg in 50 µl for
topical and 30 µg and 6 µg in 300 µl for intraperitoneal injection,
but reduced or no effect, respectively, was observed on wound
healing (data not shown).
Granulation tissue in treated wounds Granulation tissue is
composed of new blood vessels, fibroblasts, collagen, and macro-
phages. Because Tβ4 treatment enhanced wound healing, we
investigated which of the cell types involved in the granulation
tissue might be effected by treatment. Previous work had shown that
Tβ4 is a potent angiogenic factor acting as a specific chemoattractive
factor for endothelial cells and stimulating in vivo angiogenesis in
the subcutaneous mouse Matrigel plug model (Malinda et al, 1997).
We investigated whether the healing wounds showed any increase
in angiogenesis. Figure 3 shows a comparison of typical control
(d ) and Tβ4-treated (e and f ) sections of 7 d wounds. Treatment
with Tβ4 resulted in considerable capillary ingrowth (Fig 3e and
f, arrows). Vessel counts showed a significant (almost 2-fold) increase
in the number of vessels in Tβ4-treated wounds (Table 1). No
increases in the number of macrophages in the wounds were
observed, agreeing with previous in vitro findings that Tβ4 did not
stimulate macrophage migration. We did observe an increase in
the accumulation/biosynthesis of collagen in treated Tβ4-wounds
(Fig 5b and c vs a) supporting the observation of decreased wound
width and suggesting a role for Tβ4 in wound contraction. Both
the topical and the systemically treated wounds appeared similar,
Table I. Morphometric measurement of control and
thymosin b4-treated samplesa
Parameters Control I.p. Topical
Epidermal 2403.3 6 9.7 3168.3 6 38.4* 3668.7 6 56.6*
migration (µm)
Epidermal 128.2 6 19.3 135.0 6 11.7 142.3 6 19.8
thickness (µm)
Vessels/10 HPF 1364.0 6 15.0 2415.0 6 24.3* 2186.0 6 11.8*
aHPF, high power field. *P ø 0.00001 by Welch’s t-test, significantly different
than control (n 5 6).
Figure 3. Histologic sections of 7 d wounds showing
reepithelialization and angiogenesis. Arrows indicate
the edges of the original wound. (a) Control wound treated
with saline. Migration of the epithelium is visible at the
wound edge and debris is visible over the unhealed
wound. (b) Increased reepithelialization of the wound
occurred when Tβ4 was injected intraperitoneally (60 µg
per 300 µl on alternate days). (c) Topical treatment (5 µg
per 50 µl of Tβ4) resulted in complete reepithelialization
of the wound epidermis. Boxed areas are the location of
the higher magnification fields (d–f ). (d–f ) Dermis near
dermal and epidermal junction. (d ) Control showing few
cells near the dermis and little neovascularization. (e, f )
Dermis showing granulation tissue infiltrated with
fibroblasts and extensive neovascularization (arrowheads). (e)
Intraperitoneal treatment and ( f ) topical application both
resulted in significant new capillaries. Scale bar: 1 mm.
although the wound contraction proceeded slightly more quickly
with the topical treatment. Thus, Tβ4 appears to stimulate some
of the cells/processes involved in granulation tissue formation,
including angiogenesis and collagen deposition.
Keratinocyte migration in vitro Previously we had found
that Tβ4 promoted endothelial cell migration but did not effect
fibroblasts, smooth muscle, neutrophil, or monocyte migration
(Malinda et al, 1997). Based on the rapid reepithelialization observed
with Tβ4 treatment, we next tested the effect of Tβ4 on keratino-
cyte migration in vitro. Boyden chamber assays with two types of
mouse keratinocytes demonstrated that the cells migrated in
response to Tβ4 after 4–5 h. Migration was enhanced 2–3-fold
(p ø 0.003) over migration in the presence of media alone (Fig 6)
and the maximal responding doses exceeded the positive control.
The effect of Tβ4 on migration, while showing slightly differing
dose curves depending on the cell preparation and source, clearly
showed a biphasic pattern with 1000 ng per ml and 0.01 ng per
ml showing the most migration and the middle doses showing less
stimulation (but still greater than control media) in all four assays.
DISCUSSION
Angiogenic factors can potentially enhance repair in both chronic
and acute wounds. We have been analyzing thymic peptides to
determine if these potent angiogenic factors play a role in healing.
Thymosin α1 has been previously identified as an angiogenic factor
that stimulates healing in rats (Malinda et al, 1998). Another thymic
Figure 4. Tb4 reduced wound width when applied topically or
injected intraperitoneally. (a) Topical treatment with 5 µg of Tβ4 in
50 µl on the day of wounding and every 48 h, resulted in a 15% decrease
in wound width as compared with the saline controls as early as 4 d after
wounding and continued until day 7. Measurements are expressed as the
mean % decrease 6 SEM: day 4, n 5 8; day 7, control, n 5 7; treated,
n 5 5. (b) Intraperitoneal injection of Tβ4 60 µg in 300 µl on the day of
wounding and every other day resulted in a 18% decrease in wound width
relative to saline-treated controls. This trend was observed on the fourth
day post-wounding and continued through day 7 (*p ø 0.0001, **p ø 0.08,
significant difference from media alone, Student’s t-test). Measurements
are expressed as the mean % decrease 6 SEM: day 4, control, n 5 16;
treated, n 5 18; day 7, control, n 5 14; treated, n 5 16.
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Figure 5. Histologic sections of 7 d wounds showing
collagen deposition/accumulation. Masson’s trichrome
staining shows collagen in blue and endothelial cells in red.
(a) Low magnification view of a control wound treated
with saline. (b, c) Low magnification views of wounds
where Tβ4 was injected intraperitoneally (b) or applied
topically (a). Boxed areas are the location of the higher
magnification fields (d–f ). Arrows indicate the edges of the
original wound. (d ) Control wound at higher magnification
showing baseline collagen accumulation. Treatment
intraperitoneally (e) or ( f ) topically resulted in enhanced
collagen production/accumulation compared with wounds
treated with saline. Scale bar: 1 µm.
peptide, Tβ4, was also found to be an angiogenic factor, specifically
stimulating endothelial cell migration. Both are active at the 1 ng
per ml level for endothelial cell migration in the Boyden chamber
assay (Malinda et al, 1997, 1998). Tβ4 also stimulated in vivo
migration/angiogenesis and was found to be upregulated 4–6-fold
after endothelial cells have begun to make capillary-like structures
on Matrigel. In this study, we report the effect of Tβ4 on wound
healing in a rat full thickness cutaneous wound model.
The initial studies using the punch wound model in normal
rats showed that Tβ4 significantly stimulated wound closure.
Stimulation was observed starting as early as 4 d post-wounding
and proceeded at an accelerated rate through termination of the
experiment at 7 d. Both topical application and intraperitoneal
injection were equally effective in stimulating reepithelialization as
measured by gap closure at day 7. When wound contraction was
assessed, topical application appeared to be slightly more effective
based on day 7 post-wounding measurements (24% decrease vs
18% decrease). The potent nature of local application is especially
significant in that it would be easier to administer and would
prevent any possible side-effects of systemic neovascularization.
Histologic observation also showed that treated wounds were
healing faster than control wounds. At days 4 (data not shown)
and 7, significantly more blood vessels were observed in both the
topically and the intraperitoneally treated wounds. As blood vessels
are an essential early response to wounding, increased neovasculariz-
ation resulting from Tβ4 may be one of the factors responsible for
enhanced healing. Tβ4 has been previously identified in wound
fluid (Frohm et al, 1996) and is present in high concentrations (as
high as 560 µm) (Weber et al, 1992) in platelets. Because platelets
are the first cells to arrive at the site of injury and are responsible
for releasing chemoattractive factors to attract monocytes and
neutrophils to begin repair, they may also actively release Tβ4 that
attracts endothelial cells and promotes angiogenesis. Additionally,
we observed the increased deposition of well-organized collagen.
This additional collagen in the treated wounds may explain the
increased contraction observed, and may also affect the tensile
strength of the wound. It is not clear if the increased collagen is
due to the better supply of nutrients from the vessels or if Tβ4
affects collagen synthesis. Further studies are necessary to determine
the effects of Tβ4 on collagen production.
The increased gap closure observed in treated wound appears,
in part, to be due to Tβ4 promoting keratinocyte migration.
Boyden chamber assays demonstrate that Tβ4 stimulates migration
at as low as 0.01 ng per ml and with concentrations as high as 1 µg
per ml. Less migration was observed at the 0.1–10 ng per ml range.
The biphasic nature of the keratinocyte response to Tβ4 was highly
reproducible and may relate to differences in the amount of Tβ4
present during the normal wound healing process. It is possible
that Tβ4 is released at high concentrations at the time of injury by
platelets. The keratinocytes could initially respond to the Tβ4 by
migrating into the wound. Levels of Tβ4 could then maintain
keratinocyte migration into the wound. Stimulation at very low
levels could be useful in promoting a migratory response in
keratinocytes farther away from the injury site.
Figure 6. Tb4 stimulated keratinocyte migration in Boyden
chamber assays. Tβ4 in the lower wells of the chamber resulted in a 2–
3-fold increase in migration on filters coated with collagen IV. The positive
control, conditioned media, also showed increased migration over media
alone. This result is representative of four experiments. Each data point is
the average of triplicate measurements. Data points are expressed as the
mean number of migrated cells 6 SEM. (*p ø 0.003, **p ø 0.01,
significant difference from media alone, Student’s t-test.)
In preliminary experiments, we also observed that Tβ4 enhanced
wound healing in an impaired model. Steroid-treated rats showed
a significant increase in the level of healing when Tβ4 was added
topically or injected intraperitoneally (data not shown). At the
initial time point, day 4, topically treated animals showed little
response (ø7% gap or width closure, n 5 3) compared with saline
treatment. Intraperitoneal injection, however, resulted in a 28%
(612%, n 5 10 treated, five controls) decrease in gap size and a
14% (66%) decrease in wound width. At day 7, response was
observed with both topical treatment and intraperitoneal injection.
The gap in topically treated animals decreased by 39% (631%,
n 5 6) compared with saline treatment. The wound width decreased
by 23% (612%). Intraperitoneal injection resulted in a 26% (614%,
n 5 10) decrease in gap size and a 10% (65%) decrease in wound
width. Taken together, these results suggest that Tβ4 may be a
useful addition to the treatment of chronic, as well as acute wounds.
Tβ4 has a number of characteristics unlike other angiogenic
wound factors. First of all, Tβ4 does not promote cell growth but
only appears to affect cell migration. Tβ4 has no signal sequence
(Gondo et al, 1987) but is found in serum (Naylor et al, 1984;
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Weller et al, 1988). This may be due to its small size, which allows
it to diffuse out of cells that produce it, or because it is released by
damaged or dying cells (Gomez-Marquez et al, 1989). It does not
appear to bind heparin or other matrix molecules, suggesting it can
rapidly diffuse throughout tissues. Currently, no receptors have
been identified. Tβ4 is also a very potent migration factor with
activity at 1 ng (for endothelial cells) or 10 pg (for keratinocytes).
The potent effects of intraperitoneally injected Tβ4 support its
high diffusibility in tissues. Based on a previous study where
thymosin α1 was also found to promote wound repair, we believe
that the thymic peptides may represent a new class of potent wound
healing agents that may be of clinical importance.
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